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Abstract
Background: Influenza vaccination in infants and children with existing health complications is current practice in 
many countries, but healthy children are also susceptible to influenza, sometimes with complications. The under-
recognised burden of disease in young children is greater than in elderly populations and the number of paediatric 
influenza cases reported does not reflect the actual frequency of influenza.
Discussion: Vaccination of healthy children is not widespread in Europe despite clear demonstration of the benefits of 
vaccination in reducing the large health and economic burden of influenza. Universal vaccination of infants and 
children also provides indirect protection in other high-risk groups in the community. This paper contains the Central 
European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the vaccination of infants 
and children against influenza. The aim of CEVAG is to encourage the efficient and safe use of vaccines to prevent and 
control infectious diseases.
Summary: CEVAG recommends the introduction of universal influenza vaccination for all children from the age of 6 
months. Special attention is needed for children up to 60 months of age as they are at greatest risk. Individual countries 
should decide on how best to implement this recommendation based on their circumstances.
Background
Influenza is a serious infectious disease that continues to
contribute to significant morbidity and mortality world-
wide. The WHO estimates up to five million cases annu-
ally with mortality between 250,000 and 500,000 in the
industrialised world [1]. In Europe excess deaths due to
influenza are estimated to be between 40,000 and 220,000
per season. Yearly influenza vaccination benefits have
been demonstrated and vaccination for high-risk groups
is well recognised in Europe and the rest of the world as a
means of preventing infection and the complications that
develop from influenza such as pneumonia [1-4]. High-
risk groups include infants and children with existing
health complications as well as the elderly (>65 years of
age) and vaccination of these groups is current practice in
many countries. Within the member states of the Euro-
pean Union there is an objective to achieve over 75% vac-
cination coverage in elderly populations. However, there
are no such objectives in paediatric populations within
Europe despite the evidence that healthy children are sus-
ceptible to influenza, sometimes with complications [5].
The burden of disease in infants is greater than in elderly
populations [6,7] and rates of hospitalisation attributable
to influenza are similar to those in older adults. To reflect
this morbidity, universal influenza vaccination in all chil-
dren from the age of 6 months up to 18 years is current
practice in the USA and from 6 to 23 months in Canada
[8,9]. Universal vaccination of healthy children is not
widespread in Europe despite clear demonstration of the
benefits of vaccination in reducing the large health and
economic burden of influenza [10]. In Central Europe
guidelines on paediatric influenza immunisation have not
been made to date and the current report represents a
summary of evidence and the formulation of advisory
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guidelines to help decision-making about paediatric
influenza immunisation.
Discussion
The under-recognised burden of influenza in children
The burden of influenza in children is under-recognised
[11-13]. The incidence of influenza in children under 5
years of age is far greater than in the elderly, with esti-
mates showing an attack rate of 30% and respiratory ill-
nesses peaking in the age group at 1-2 years [7]. Although
overall influenza-associated mortality rates in children
were not high, a US study showed 63% of the 153
reported influenza-associated paediatric deaths during
the 2003-04 influenza season were less than 5 years of age
[14]. In this study 33% had an underlying condition
known to increase the risk of influenza-related complica-
tions and 20% had other chronic conditions; however,
47% had previously been healthy.
Children under 2 years of age are at highest risk of
influenza and are most likely to develop serious compli-
cations such as pneumonia, secondary bacterial infection,
and sepsis [15]. Excess hospitalisations are high in young
children, particularly those younger than 12 months of
age. Healthy children under one year of age are hospital-
ised for influenza-associated illnesses at similar rates to
those for adults in high-risk groups [16]. The high rate of
hospitalisation in children was largely responsible for
introduction of universal vaccination in the USA. Despite
high rates of hospitalisation, influenza cases are generally
under-reported and it is likely that the number of notified
cases does not reflect the real-life frequency of influenza.
Influenza infections are frequently unrecognised clini-
cally despite contributing to significant numbers of hos-
pitalisation (annual rate 0.9 per 1000 children) [13].
The largest proportion of paediatric influenza-related
illness is associated with the outpatient setting [5]. Out-
patient visits associated with influenza in young children
are 10- to 250-fold more common than hospitalised cases
[13]. Children between the ages of 6 and 23 months have
the highest rates of visits to clinics and emergency
departments attributable to influenza [13]. These medi-
cally-attended influenza cases are also under-reported
due to the potential for incorrect diagnosis and lack of
laboratory confirmation. Laboratory confirmation is fre-
quently not used to diagnose influenza in young children
and rarely used in the outpatient setting. The diagnosis of
influenza is usually made on the basis of patient history,
clinical signs and symptoms and knowledge of the local
epidemiological situation. Due to overlap of symptoms
with other respiratory disease infection, influenza in chil-
dren is easily misdiagnosed [13].
Typical symptoms of early influenza include mainly
sudden high fever, cough and absence of rhinitis. Chil-
dren do not always show these symptoms. Whilst high
fever is a prominent sign of influenza, unlike adults, many
children treated for influenza in the outpatient setting
present with rhinitis during the early phase of the illness,
making clinical distinction from a 'cold' difficult in this
age group [17]. In young children the clinical presenta-
tions of influenza-related illness can consist of pneumo-
nia, croup, bronchitis and sepsis, and these conditions
might not be attributed to influenza if laboratory-con-
firmed data are not available [15]. Several rapid antigen
detection tests are available and provide results in 10-30
min but with reduced sensitivity (70%-90% in children)
compared with RT-PCR and with viral culture. Accuracy
of these assays depends greatly on patient age, length of
illness, sample type, and possibly viral type [18]. Our
understanding of the clinical presentation of paediatric
influenza is based only on studies examining hospitalised
children with severe forms of influenza which may alter
our perception concerning the signs and symptoms of
influenza in children [17]. It has been shown that for chil-
dren with laboratory-confirmed influenza, only 28% of
hospitalised children and 17% of children seen in the
clinic are correctly diagnosed by their treating physicians
[13]. The accuracy of diagnosis is poor, particularly in the
early and late phases of outbreaks [19]. Clinical diagnosis
is poorest in children under 3 years of age, the group that
has the greatest burden of disease from influenza. In this
group a clinical diagnosis sensitivity of 21% and positive
predictive value of 16% were observed [19]. One result of
low diagnosis is that the number of cases reported does
not reflect the actual frequency of influenza. The use of
rapid testing for influenza may enhance the precision of
the influenza diagnosis but the reduced sensitivity of
these tests means that negative test results should be con-
firmed with RT-PCR and/or viral culture [18,20].
Influenza vaccine
The efficacy and effectiveness of trivalent inactivated vac-
cine (TIV) in healthy children (under 19 years of age) has
been examined in a number of meta-analyses, overall
vaccine efficacy estimates were similar for laboratory-
confirmed influenza (59-63%) and clinical cases (36-45%)
[21-23]. Lower estimates for clinically diagnosed cases
are possibly due to inclusion of misdiagnosed non-influ-
enza cases and a proportion of cases that would not be
prevented even with a totally efficacious vaccine [22]. All
three meta-analysis studies highlight a lack of extensive
data for children less than 2 years of age that preclude
meaningful analysis.
For children aged less than 5 years the vaccine efficacy
against influenza is broad ranging, from 12 to 83% [24].
The efficacy and effectiveness of influenza vaccinations
depends on several factors, most importantly on the age
and immunocompetence of the recipient, the similarity
between the viruses in the vaccine and in circulation for aUsonis et al. BMC Infectious Diseases 2010, 10:168
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given influenza season, and the study design and out-
come measured [8]. A recent case-control study over
eight consecutive influenza seasons from 1999-2000
through 2006-07 has shown that TIV is highly effective in
preventing laboratory-confirmed influenza in children <5
years of age when given as recommended by the Ameri-
can Academy of Pediatrics and the Advisory Committee
on Immunization Practices (ACIP) of the Centers for Dis-
ease Control and Prevention (CDC), with effectiveness
estimates of 86% [25].
Relatively few studies on influenza vaccine efficacy and
effectiveness have been conducted in children aged
between 6 and 23 months [26-28]. In one randomised
clinical study in this age group, vaccine efficacy against
culture-confirmed influenza was 66% during the 1999-
2000 influenza season; however there was no significant
reduction of culture-confirmed influenza during the
2000-01 season. It was noted that the attack rate was
higher (15.9%) in the first season compared to the second
(3.3%) [26]. In a retrospective cohort study in children 6
to 23 months of age, vaccine effectiveness was 25%
against influenza-like illnesses and 49% against pneumo-
nia or influenza during the 2003-04 influenza season [27].
In another retrospective study examining healthy chil-
dren aged 6-21 months, vaccine effectiveness after two
doses was estimated to be 87% against pneumonia or
influenza-related office visits [28]. The influenza cases in
both studies were not laboratory-confirmed.
The influenza vaccines currently approved for children
and adults in Europe contain three strains of influenza
viruses that are recommended annually by the WHO
based on global surveillance. The vaccine contains one
influenza A(H3N2) strain, one influenza A(H1N1) strain,
and one influenza B strain and may change each year to
reflect the most recent circulating forms of the virus. TIV
is approved for use in children aged 6 months or more, as
well as adults, and includes populations who have chronic
medical conditions and women who are pregnant. There
is currently no vaccine recommended for children less
than 6 months of age.
An annual booster of influenza vaccine is recom-
mended for all age groups. The TIV is injected into the
deltoid muscle and does not cause influenza although
minor side effects are noted. Inactivated influenza vac-
cines contain trace levels of egg protein so that individu-
als with allergies to egg protein should not receive the
vaccine.
The inactivated influenza vaccine is safe and well-toler-
ated in children [29,30]. It very rarely causes immediate
allergic reactions and there is no evidence of an increase
in asthma exacerbations [31]. The risk of developing
Guillain-Barré syndrome following influenza vaccination
is at most one in 1,000,000 [8]. There is no evidence of
any preventive effects of homeopathic supplements
against influenza [32].
Influenza vaccines are the mainstay of efforts to reduce
the substantial global health burden that influenza poses.
In the USA influenza vaccination is recommended for all
children six months of age or older, adults 50 years old or
older, all individuals with chronic medical conditions and
pregnant women, as well as people in contact with sus-
ceptible groups, such as health-care professionals. Given
the global disease burden of influenza, the WHO has
indicated that member states should evaluate the cost-
effectiveness of introducing influenza vaccination into
national immunisation programmes [33].
In Europe two doses of trivalent inactivated influenza
vaccine are recommended in previously unvaccinated
infants and children [34]. The two doses are administered
at least one month apart for children aged 6 months to 8
or 9 years (depending on manufacturer's recommenda-
tions) who either receive an influenza vaccine for the first
time or have not been exposed to influenza previously.
Despite recommendations of multiple doses, young chil-
dren often only receive one injection of influenza vaccine
for primary vaccination. For children under 3 years of age
a half dose is required per injection. For older children
receiving the seasonal influenza vaccine for the first time,
a single dose of the vaccine is appropriate. However, opti-
mal dosage and scheduling in infants and children is cur-
rently not well established.
In the USA the number of influenza vaccine doses
administered is age-dependent [8]. Children who are 9
years old or older who have not been vaccinated previ-
ously require one dose in their first season of immunisa-
tion. Children under the age of 9 years being vaccinated
for the first time receive a second dose at least 4 weeks
after the first. Children younger than 9 years of age who
received only one dose of vaccine in the first season they
were vaccinated should receive two doses of influenza
vaccine the following season; this applies only to the
influenza season that follows the first year that the child
receives influenza vaccine.
In Canada children under 9 years of age who have never
received an influenza vaccine require two doses adminis-
tered 4 weeks apart [9]. Those who have been vaccinated
with one dose in the previous year require two doses,
while those who received two doses in the previous year
would only require one dose. Children receiving vaccine
for the third year or longer would only require one dose.
Before implementing any universal vaccination scheme
it is vital to consider in addition to disease burden the
safety of the vaccine to the recipient and to the whole
population and the expectation of significant publicUsonis et al. BMC Infectious Diseases 2010, 10:168
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health benefits with a demonstration of cost-effective-
ness. The indirect benefit to the community of vaccinat-
ing healthy children, mostly of school age, has been
evaluated in a systematic review and found to be poten-
tially beneficial to the children and capable of generating
significant health benefits and cost saving for the wider
community [35].
In Europe the prevailing immunisation strategy is to
prevent seasonal influenza primarily by protecting vul-
nerable (those at high risk) individuals as opposed to
achieving herd immunity and reduce transmission in the
community via universal vaccination. There is increasing
support for immunising healthy children against influ-
enza with the appreciation that children bear the vast
burden of disease. Vaccination of children will protect
against viral infection but will also protect against two
common bacterial complications: otitis media and pneu-
monia. In addition to the direct benefit of reducing the
burden of disease in children there is the indirect effect of
reducing transmission by protecting unvaccinated adults
against infection. Children are the main transmitters of
the influenza virus during local outbreaks as they shed
greater quantities of the virus and for longer periods of
time than adults [12,36-38]. Universal vaccination of
infants and children could result in decreased morbidity
and mortality in other high-risk groups in the community
[35].
As long ago as 1970 Monto et al. showed that indirect
protection of adults was achieved by vaccinating school-
children [39]. In Japan the overall influenza-associated
mortality rates were lowest during the winters of 1977-87
when influenza vaccination in Japanese schools was com-
pulsory [40]. With around 60% of Japanese families con-
sisting of grandparents also living in the same household,
immunisation of all schoolchildren protected other at-
risk members in their family. During the influenza epi-
demic of 1968-69 in the USA, in which 85% of schoolchil-
dren had been vaccinated, overall respiratory illness rates
dropped to one-third of the rates observed in an unvacci-
nated population [39] while vaccination of day care chil-
dren (aged 24-60 months) reduced the incidence of
febrile respiratory illnesses in unvaccinated family mem-
bers by 42% [41]. Similar findings were reported in Italy
where vaccination of children younger than 14 years sig-
nificantly decreased the cases of respiratory infections
and absenteeism from work among household contacts
[42].
In addition to the community-wide protection against
influenza provided by vaccinating children, there are
potentially significant cost-related benefits. Indirect costs
avoided include parental time costs, absence from work,
loss of earnings and time costs among secondary cases.
Parents lose an average of 1.3 working days caring for sick
children and 0.4 days due to transmission of the infection
[5]. A study in Finland showed that for every 100 influ-
enza-infected children younger than 3 years old, 195 days
of parental work were lost (mean duration 3.2 days) [11].
It is estimated that investing 1.7 million Euros in the vac-
cination of children <5 years of age will save 2.7 million
Euros in health care costs [43]. Vaccination was found to
be cost saving even with an assumed vaccine efficacy of
60% [43].
Existing recommendations for vaccinating children against 
influenza
In 2006-07 an independent scientific panel convened by
the European Centre for Disease Prevention and Control
found that there were insufficient data to support wide-
spread immunisation of children though the vaccines did
induce immunity [34]. The review found considerable
data from outside Europe but few data relevant to Europe
itself and there was a lack of information on the European
burden of disease in children. This view has recently been
reconfirmed [44]. Although the evidence for immunisa-
tion of risk groups such as children and pregnant women
is not strong for Europe, it should be noted that there is
no evidence against immunisation of these groups [44].
The World Health Organization currently recommends
yearly vaccination against seasonal influenza for children
6-23 months of age [45].
The number of countries adopting universal vaccina-
tion of infants and children in response to the burden of
influenza in this age group is increasing. In Canada the
National Advisory Committee on Immunization cur-
rently recommends influenza vaccination for all children
aged 6-23 months of age [9]. ACIP has continuously
updated its recommendations in the USA for influenza
vaccination in children of 6-23 months of age (in 2003) to
6-59 months of age (in 2006) and finally extending their
recommendation in 2009 to include all children and ado-
lescents under the age of 19 years [8]. Interestingly, 48%
of children received the first dose of influenza vaccine in
the first year of the ACIP's recommendation for universal
influenza vaccination [46]. This vaccination rate was
higher than the vaccination rate among older children
with high-risk medical conditions, for whom influenza
vaccination has been recommended for many years. Uni-
versal age-based recommendations are more likely to be
successful than risk-based. Health-care professionals and
the public find it difficult to decide on eligibility using
risk-based recommendations. Vaccination rates for those
≥65 years of age, for whom universal influenza vaccina-
tion is recommended, are consistently higher than among
adults <65 years old with underlying high-risk conditions
[47].
A 2008 survey of the 27 EU member states together
with Norway and Iceland revealed that all countries rec-
ommended seasonal influenza vaccination in the periodUsonis et al. BMC Infectious Diseases 2010, 10:168
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2006-07 for older age groups (22 countries for those aged
>65 years) [10]. In Austria the vaccine was recommended
for all age groups. In Poland the recommendation is from
the age of 50 whilst in Hungary immunisation is recom-
mended from the age of 55. All countries recommended
vaccinating high-risk patients and this includes any per-
son irrespective of age with chronic pulmonary and car-
diovascular diseases, with haematological or metabolic
disorders, immunological disorders and renal disease, as
well as residents of long-term care facilities. Within
Europe, six countries, in addition to Austria, advise rou-
tine vaccination of children. Estonia recommends vacci-
nation of all healthy individuals from the age of 6 months
whilst Finland recommends vaccination of healthy chil-
dren between 1 and 3 years. Latvia, Romania and Slove-
nia recommend vaccination between 6 months and 2
years whilst Slovakia has a broader age range from 6
months to 5 years for vaccination of healthy children.
Whilst these countries recommend vaccination for chil-
dren, a recent study suggested that the scientific evidence
for immunising children in Europe was not strong but
acknowledged that there was no evidence against immu-
nisation of this group [44]. Table 1 summarises the cur-
rent recommendations for vaccination of children
according to country.
CEVAG
CEVAG consists of regional experts from ten Central
European countries: Bulgaria, Croatia, the Czech Repub-
lic, Estonia, Hungary, Lithuania, Poland, Romania, Slova-
kia and Turkey. The aim of CEVAG is to encourage the
efficient and safe use of vaccines to prevent, control and if
possible eradicate infectious diseases, by raising aware-
ness of immunisation and by the compilation and distri-
bution of appropriate information.
CEVAG guidance statement
CEVAG recommends the introduction of universal influ-
enza vaccination of all children, including healthy chil-
dren and those with existing health complications, from
the age of 6 months. Special attention is needed for chil-
dren up to 60 months of age as they are at greatest risk.
Individual countries should decide on how best to imple-
ment this recommendation based on their circumstances.
The CEVAG guidance statement on recommendations
for paediatric influenza immunisation is described in
Table 2.
Strategies for the future
Constant review of new immunisation strategies to pro-
tect against childhood influenza will be required in
Table 1: Countries with recommendations to vaccinate 
healthy children according to age
Country Age range
North America
Canada [9] 6-23 months
USA [8] 6 months - 18 years
Europe*
Austria ≥ 6 months
Estonia ≥ 6 months
Finland 1-3 years
Latvia 6 months - 2 years
Romania 6 months - 2 years
Slovakia 6 months - 5 years
Slovenia 6 months - 2 years
*Adapted from National Seasonal Influenza Vaccination Survey in 
Europe [56] and information provided on the Vaccinnet Romania 
website [57]
Table 2: Summary of CEVAG guidance statement on 
recommendations for influenza vaccination of all children
Consideration CEVAG recommendation
Primary target group for 
influenza vaccination
Children
Age of vaccination From 6 months of age, with special 
attention to the 6-60 month age 
group
Method of vaccine 
delivery
To fit within the existing 
vaccination schedule in the first 
and second year of life
Vaccination routine Annual vaccination. For the first 
year of vaccination, all children 
should receive two doses with 
minimum interval of 4 weeks 
according to the manufacturer's 
recommendations. In the second 
year, children should receive a 
single dose of seasonal vaccine.
For children aged between 6 and 
35 months 0.25 mL doses are 
administered, equivalent to half 
the adult dose
Commonly reported 
reactions following 
vaccination
Mild soreness, redness, and 
swelling at injection site, fever, 
and aches. These symptoms 
usually begin soon after the 
injection, and last 1-2 days
Safety concerns No safety concerns have been 
identified with the use of trivalent 
inactivated influenza vaccines 
with the exception that individuals 
with allergy to egg products 
should avoid immunisationUsonis et al. BMC Infectious Diseases 2010, 10:168
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Europe and the rest of the world. The recent spread of
2009 Influenza A(H1N1) illustrates the speed with which
new forms of the influenza virus spread around the globe
and the threat from A/H5N1 remains high. Although the
trivalent inactivated vaccine is the mainstay for paediatric
and adult vaccination, other vaccines have been investi-
gated. Most data are available on the live, attenuated, cold
adapted intranasal vaccine (LAIV) that is licensed in the
USA for children aged above 24 months and for adults
aged 18-49 years. It is not licensed outside the USA.
Recently published data from clinical trials suggest that
LAIV has a higher relative efficacy compared with TIV in
children <5 years of age [48-50]. In children aged <24
months one study suggested increased risk of wheezing
and increased risk of hospitalisation in children aged
between 6 and 11 months [49]. A subsequent smaller
study did not find any evidence for these adverse events
[50]. Another strategy for the future is the use of
enhanced adjuvants in association with inactivated influ-
enza vaccine.
The ability of an influenza vaccine to trigger an
immune response against drifted viruses not in the vac-
cine formulation is of potential clinical benefit in very
young children naive to influenza virus exposure. Anti-
genic drift of influenza viruses requires frequent adapta-
tion of vaccines to accommodate this drift. One of the
major challenges faced is to predict the drifts ahead of
i n f l u e n z a  s e a s o n s .  A d j u v a n t e d  v a c c i n e s  s u c h  a s  t h o s e
using MF59 induce significantly higher immune
responses against mismatched H3N2 and H1N1 strains
than the licensed split vaccine, they have acceptable toler-
ability and a greater immunogenicity in young children
compared with conventional split vaccines [51]. Recent
development of a vaccine against the pandemic influenza
A (H1N1) containing the adjuvant AS03 show high
immunogenicity and are well tolerated in children aged 6
to 35 months [52].
Influenza vaccines need to provide sustained protec-
tion against illness as well as being effective. Vaccination
with LAIV provides prolonged protection against influ-
enza in children between 6 and 18 years of age that lasts
5-12 months after the vaccination is first administered.
Multiple studies have shown that LAIV provides sus-
tained protection against influenza caused by antigeni-
cally similar strains through a second influenza season in
children aged 6 months to 18 years without the need to
revaccinate [53,54]. No such protection data exist for
adult populations.
The introduction of universal influenza vaccination for
all children is clearly desirable but continued education
for health-care professionals and the public on the bene-
fits of immunisation and paediatric influenza is likely to
increase acceptance of vaccination. A stronger motiva-
tion on the part of health-care professionals would also
enhance the vaccination of children. Vaccine uptake in
children across 11 European countries ranged from 4.2%
in Ireland to 19.3% in Germany with two countries of the
CEVAG region, the Czech Republic and Poland, showing
intermediate rates of 7.6 and 9.2% respectively [55].
There is little doubt that increased awareness will over-
come many of the barriers to vaccination.
Summary
•The under-recognised burden of disease in children
under 5 years is far greater than in elderly populations
•The number of paediatric influenza cases reported
does not reflect the actual frequency of influenza with
clinical diagnosis poorest in children under 3 years of age
•Universal vaccination of infants and children could
result in decreased morbidity and mortality in other
high-risk groups in the community
•CEVAG recommends the introduction of universal
influenza vaccination for all children from the age of 6
months. Special attention is needed for children up to 60
m o n t h s  o f  a g e  a s  t h e y  a r e  a t  g r e a t e s t  r i s k .  I n d i v i d u a l
countries should decide on how best to implement this
recommendation based on their circumstances.
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